NO317335B1 - Anvendelse av K-252A derivat for behandling av perifere og sentrale nerveforstyrrelser og cytokinoverproduksjon - Google Patents
Anvendelse av K-252A derivat for behandling av perifere og sentrale nerveforstyrrelser og cytokinoverproduksjon Download PDFInfo
- Publication number
- NO317335B1 NO317335B1 NO19986111A NO986111A NO317335B1 NO 317335 B1 NO317335 B1 NO 317335B1 NO 19986111 A NO19986111 A NO 19986111A NO 986111 A NO986111 A NO 986111A NO 317335 B1 NO317335 B1 NO 317335B1
- Authority
- NO
- Norway
- Prior art keywords
- compound
- disease
- neurons
- animals
- overproduction
- Prior art date
Links
- 238000012261 overproduction Methods 0.000 title claims description 13
- 102000004127 Cytokines Human genes 0.000 title description 4
- 108090000695 Cytokines Proteins 0.000 title description 4
- 210000005036 nerve Anatomy 0.000 title description 4
- 230000002093 peripheral effect Effects 0.000 title description 2
- 229940126062 Compound A Drugs 0.000 claims description 105
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 105
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 28
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 20
- 206010040070 Septic Shock Diseases 0.000 claims description 13
- 208000010668 atopic eczema Diseases 0.000 claims description 13
- 230000036303 septic shock Effects 0.000 claims description 13
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 12
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 12
- 201000004681 Psoriasis Diseases 0.000 claims description 12
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 12
- 201000010105 allergic rhinitis Diseases 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 12
- 201000008937 atopic dermatitis Diseases 0.000 claims description 12
- 206010006451 bronchitis Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 201000008482 osteoarthritis Diseases 0.000 claims description 11
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 10
- 230000004968 inflammatory condition Effects 0.000 claims description 9
- 230000009931 harmful effect Effects 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- VVVPGLRKXQSQSZ-UHFFFAOYSA-N indolo[3,2-c]carbazole Chemical compound C1=CC=CC2=NC3=C4C5=CC=CC=C5N=C4C=CC3=C21 VVVPGLRKXQSQSZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960005544 indolocarbazole Drugs 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 39
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 24
- 239000002158 endotoxin Substances 0.000 description 23
- 229920006008 lipopolysaccharide Polymers 0.000 description 22
- 208000033808 peripheral neuropathy Diseases 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 21
- 201000010099 disease Diseases 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 230000003902 lesion Effects 0.000 description 19
- 210000005064 dopaminergic neuron Anatomy 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 201000001119 neuropathy Diseases 0.000 description 15
- 230000007823 neuropathy Effects 0.000 description 15
- 239000003981 vehicle Substances 0.000 description 15
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 14
- KOZFSFOOLUUIGY-IYYJOCMQSA-N k-252a, nocardiopsis sp. Chemical class C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@@H]1C[C@](C(=O)OC)(O)[C@@]4(C)O1 KOZFSFOOLUUIGY-IYYJOCMQSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 13
- 210000001353 entorhinal cortex Anatomy 0.000 description 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 12
- 208000024827 Alzheimer disease Diseases 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 210000001362 glutamatergic neuron Anatomy 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 11
- 102100039065 Interleukin-1 beta Human genes 0.000 description 11
- 239000002246 antineoplastic agent Substances 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 102000003923 Protein Kinase C Human genes 0.000 description 10
- 108090000315 Protein Kinase C Proteins 0.000 description 10
- 231100000167 toxic agent Toxicity 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 230000004770 neurodegeneration Effects 0.000 description 9
- 239000003440 toxic substance Substances 0.000 description 9
- 208000018737 Parkinson disease Diseases 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 7
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000003291 dopaminomimetic effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 6
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 102000010909 Monoamine Oxidase Human genes 0.000 description 6
- 108010062431 Monoamine oxidase Proteins 0.000 description 6
- 206010029350 Neurotoxicity Diseases 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 206010044221 Toxic encephalopathy Diseases 0.000 description 6
- 210000001947 dentate gyrus Anatomy 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 229930195712 glutamate Natural products 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000001577 neostriatum Anatomy 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 231100000228 neurotoxicity Toxicity 0.000 description 6
- 230000007135 neurotoxicity Effects 0.000 description 6
- 208000027232 peripheral nervous system disease Diseases 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000003492 excitotoxic effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 239000002581 neurotoxin Substances 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 210000004129 prosencephalon Anatomy 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- IRJCBFDCFXCWGO-SCSAIBSYSA-N (2r)-2-azaniumyl-2-(3-oxo-1,2-oxazol-5-yl)acetate Chemical compound [O-]C(=O)[C@H]([NH3+])C1=CC(=O)NO1 IRJCBFDCFXCWGO-SCSAIBSYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- IRJCBFDCFXCWGO-UHFFFAOYSA-N Ibotenic acid Natural products OC(=O)C(N)C1=CC(=O)NO1 IRJCBFDCFXCWGO-UHFFFAOYSA-N 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- BTFHLQRNAMSNLC-UHFFFAOYSA-N clorgyline Chemical compound C#CCN(C)CCCOC1=CC=C(Cl)C=C1Cl BTFHLQRNAMSNLC-UHFFFAOYSA-N 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 231100000318 excitotoxic Toxicity 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000002052 molecular layer Substances 0.000 description 4
- 210000004126 nerve fiber Anatomy 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 229960004528 vincristine Drugs 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000004060 excitotoxin Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- 108010007979 Glycocholic Acid Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 2
- KZKGLGIVGQYOTG-UHFFFAOYSA-N [F].[Au] Chemical compound [F].[Au] KZKGLGIVGQYOTG-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000006736 behavioral deficit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 229960002656 didanosine Drugs 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000003371 gabaergic effect Effects 0.000 description 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical group C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 229940114072 12-hydroxystearic acid Drugs 0.000 description 1
- QIMGSZURBOTPMW-UHFFFAOYSA-N 2-methoxy-5-(2,3,4-trimethoxyphenyl)cyclohepta-2,4,6-trien-1-one Chemical compound COC1=C(OC)C(OC)=CC=C1C1=CC=C(OC)C(=O)C=C1 QIMGSZURBOTPMW-UHFFFAOYSA-N 0.000 description 1
- QJTQKPNNQVLHHO-UHFFFAOYSA-N 9h-carbazole;1h-indole Chemical compound C1=CC=C2NC=CC2=C1.C1=CC=C2C3=CC=CC=C3NC2=C1 QJTQKPNNQVLHHO-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022031 Inherited neuropathies Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102100030783 Myosin light chain kinase 3 Human genes 0.000 description 1
- 101710198035 Myosin light chain kinase, smooth muscle Proteins 0.000 description 1
- SJLBIPLIGYWGJV-UHFFFAOYSA-N N-nitroso-N-methyl-4-aminobutyric acid Chemical compound O=NN(C)CCCC(O)=O SJLBIPLIGYWGJV-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000001163 Tangier disease Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 description 1
- 230000007845 axonopathy Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000028436 dopamine uptake Effects 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 210000004002 dopaminergic cell Anatomy 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000001905 globus pallidus Anatomy 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 231100000663 medical toxicology Toxicity 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000006764 neuronal dysfunction Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- -1 staurosporine oximes Chemical class 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000001977 striatum neuron Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-N tetraethylazanium;hydrochloride Chemical compound Cl.CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2040696P | 1996-06-25 | 1996-06-25 | |
| PCT/US1997/010898 WO1997049406A1 (en) | 1996-06-25 | 1997-06-24 | Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO986111D0 NO986111D0 (no) | 1998-12-23 |
| NO986111L NO986111L (no) | 1999-02-23 |
| NO317335B1 true NO317335B1 (no) | 2004-10-11 |
Family
ID=21798468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19986111A NO317335B1 (no) | 1996-06-25 | 1998-12-23 | Anvendelse av K-252A derivat for behandling av perifere og sentrale nerveforstyrrelser og cytokinoverproduksjon |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6184217B1 (enExample) |
| EP (1) | EP0912184B1 (enExample) |
| JP (2) | JP2000514420A (enExample) |
| CN (1) | CN1108799C (enExample) |
| AT (1) | ATE224718T1 (enExample) |
| AU (1) | AU721942B2 (enExample) |
| BR (1) | BR9710693A (enExample) |
| DE (1) | DE69715862T2 (enExample) |
| DK (1) | DK0912184T3 (enExample) |
| ES (1) | ES2184106T3 (enExample) |
| NO (1) | NO317335B1 (enExample) |
| NZ (1) | NZ333441A (enExample) |
| PT (1) | PT912184E (enExample) |
| RU (1) | RU2183959C2 (enExample) |
| UA (1) | UA65542C2 (enExample) |
| WO (1) | WO1997049406A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6127401A (en) * | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
| US6200968B1 (en) * | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
| CA2345295C (en) | 1998-09-25 | 2009-12-15 | Cephalon, Inc. | Use of fused pyrrolocarbazoles in preventing/treating damage to sensory hair cells and cochlear neurons |
| MXPA01003761A (es) | 1998-10-13 | 2003-07-21 | Kyowa Hakko Kogyo Kk | Agente para tratar oftalmopatia. |
| JP2000290184A (ja) * | 1999-04-01 | 2000-10-17 | Kyowa Hakko Kogyo Co Ltd | 経鼻投与製剤 |
| CA2396165C (en) * | 2000-01-14 | 2011-01-04 | John F. Hunt | Airway alkalinization as therapy for airway diseases |
| AU2001261324A1 (en) * | 2000-05-08 | 2001-11-20 | Psoriasis Research Institute | Psoriasis treatment |
| US7129250B2 (en) | 2000-05-19 | 2006-10-31 | Aegera Therapeutics Inc. | Neuroprotective and anti-proliferative compounds |
| US7018999B2 (en) | 2001-05-16 | 2006-03-28 | Cephalon, Inc. | Methods for the treatment and prevention of pain |
| WO2004058190A2 (en) * | 2002-12-23 | 2004-07-15 | Rinat Neuroscience Corp. | Methods for treating taxol-induced sensory neuropathy |
| PL1606409T3 (pl) | 2003-03-19 | 2011-02-28 | Biogen Ma Inc | Białko wiążące receptor Nogo |
| JP2006520806A (ja) * | 2003-03-20 | 2006-09-14 | ライナット ニューロサイエンス コーポレイション | タキソール誘導性腸障害を処置する方法 |
| TWI324604B (en) * | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
| EP1646372A2 (en) * | 2003-07-14 | 2006-04-19 | Decode Genetics EHF. | Methods of diagnosis and treatment for asthma based on haplotype association |
| US20060014165A1 (en) * | 2003-07-14 | 2006-01-19 | Decode Genetics Ehf. | Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association |
| WO2005014003A1 (en) * | 2003-07-23 | 2005-02-17 | Creabilis Therapeutics S.R.L. | Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation |
| WO2005082920A1 (en) | 2004-02-27 | 2005-09-09 | H. Lundbeck A/S | Crystalline forms of a pharmaceutical compound |
| PL1776136T3 (pl) | 2004-06-24 | 2013-03-29 | Biogen Ma Inc | Leczenie stanów związanych z demielinizacją |
| MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| AR054260A1 (es) * | 2005-04-26 | 2007-06-13 | Rinat Neuroscience Corp | Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos |
| SG10201508322SA (en) | 2005-07-08 | 2015-11-27 | Biogen Ma Inc | Sp35 antibodies and uses thereof |
| EP2068866A4 (en) | 2006-07-24 | 2010-04-07 | Biogen Idec Inc | METHODS FOR PROMOTING MYELINIZATION, NEURONAL SURVIVAL AND DIFFERENTIATION OF OLIGODENDROCYTES BY ADMINISTERING SP35 OR TRKA ANTAGONISTS |
| WO2010005570A2 (en) | 2008-07-09 | 2010-01-14 | Biogen Idec Ma Inc. | Compositions comprising antibodies to lingo or fragments thereof |
| MX381731B (es) | 2012-05-14 | 2025-03-13 | Biogen Ma Inc | Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras. |
| HK1246810A1 (zh) | 2015-01-08 | 2018-09-14 | Biogen Ma Inc. | Lingo-1对抗药及用於治疗脱髓鞘疾病的用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041489A (ja) * | 1983-08-12 | 1985-03-05 | Kyowa Hakko Kogyo Co Ltd | 新規生理活性物質ｋ―２５２ |
| US4554402A (en) | 1983-12-23 | 1985-11-19 | Aluminum Company Of America | Vibration damper for overhead conductor |
| JPS62120388A (ja) | 1985-11-19 | 1987-06-01 | Meiji Seika Kaisha Ltd | Ｓｆ−２３７０物質ハロゲン化誘導体とその製造法 |
| JPS62155284A (ja) | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | 生理活性物質ｋ−２５２の誘導体 |
| JPS62155285A (ja) | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | 生理活性物質ｋ−２５２の誘導体 |
| JPS62220196A (ja) | 1986-03-20 | 1987-09-28 | Kyowa Hakko Kogyo Co Ltd | 新規物質ｕｃｎ―０１ |
| US4816450A (en) | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
| JPH0826036B2 (ja) | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質ｋ−２５２の誘導体 |
| US4735939A (en) | 1987-02-27 | 1988-04-05 | The Dow Chemical Company | Insecticidal activity of staurosporine |
| EP0303697B1 (en) | 1987-03-09 | 1997-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
| IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| JPH07113027B2 (ja) | 1987-12-24 | 1995-12-06 | 協和醗酵工業株式会社 | Ｋ−２５２誘導体 |
| WO1989007105A1 (fr) | 1988-02-04 | 1989-08-10 | Kyowa Hakko Kogyo Co., Ltd. | Derives de staurosporine |
| DE3835842A1 (de) | 1988-10-21 | 1990-04-26 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel |
| DE3924538A1 (de) | 1989-07-25 | 1991-01-31 | Goedecke Ag | Indolocarbazol und dessen verwendung |
| AU7035991A (en) | 1989-12-14 | 1991-07-18 | Schering Corporation | Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856 |
| JPH0586068A (ja) | 1991-03-04 | 1993-04-06 | Rikagaku Kenkyusho | 新規抗生物質ｒｋ−１４０９、その製造法並びに抗腫瘍剤及び抗炎症剤 |
| WO1993008809A1 (en) | 1991-11-08 | 1993-05-13 | The University Of Southern California | Compositions containing k-252 compounds for potentiation of neurotrophin activity |
| JP2593021B2 (ja) | 1991-12-13 | 1997-03-19 | 伊藤ハム株式会社 | ウシ胚の性の識別方法 |
| RU2045575C1 (ru) * | 1992-01-29 | 1995-10-10 | Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов | Рекомбинатная плазмидная днк ppr - tgatg - hil - 1 beta - tsr, обеспечивающая синтез рекомбинантного интерлейкина-1 и штамм escherichia coli - продуцент рекомбинантного интерлейкина-1 бета человека |
| US6271242B1 (en) | 1992-02-10 | 2001-08-07 | Bristol-Myers Squibb Co. | Method for treating cancer using a tyrosine protein kinase inhibitor |
| JPH05247055A (ja) | 1992-03-03 | 1993-09-24 | Meiji Seika Kaisha Ltd | スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤 |
| US5344926A (en) | 1992-06-22 | 1994-09-06 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing staurosporine derivatives |
| JPH0673063A (ja) | 1992-06-22 | 1994-03-15 | Kyowa Hakko Kogyo Co Ltd | Ｕｃｎ−０１誘導体 |
| US5621100A (en) | 1992-07-24 | 1997-04-15 | Cephalon, Inc. | K-252a derivatives for treatment of neurological disorders |
| US5461146A (en) * | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
| GB9215921D0 (en) * | 1992-07-27 | 1992-09-09 | Wellcome Found | Anti-inflammatory compounds |
| EP0839814A3 (en) | 1993-05-28 | 1998-09-16 | Cephalon, Inc. | Indolocarbazole derivatives and their use for the treatment of prostate gland disorders |
| JPH08511785A (ja) | 1993-06-17 | 1996-12-10 | チバ−ガイギー アクチェンゲゼルシャフト | プロテインキナーゼｃ阻害剤として有用なインドロカルバゾール |
| WO1995022331A1 (en) * | 1994-02-18 | 1995-08-24 | Cephalon, Inc. | Aqueous indolocarbazole solutions |
-
1997
- 1997-06-24 WO PCT/US1997/010898 patent/WO1997049406A1/en not_active Ceased
- 1997-06-24 ES ES97930203T patent/ES2184106T3/es not_active Expired - Lifetime
- 1997-06-24 AT AT97930203T patent/ATE224718T1/de active
- 1997-06-24 BR BR9710693-3A patent/BR9710693A/pt not_active IP Right Cessation
- 1997-06-24 DK DK97930203T patent/DK0912184T3/da active
- 1997-06-24 JP JP10503444A patent/JP2000514420A/ja active Pending
- 1997-06-24 PT PT97930203T patent/PT912184E/pt unknown
- 1997-06-24 US US08/881,679 patent/US6184217B1/en not_active Expired - Lifetime
- 1997-06-24 CN CN97197341A patent/CN1108799C/zh not_active Expired - Lifetime
- 1997-06-24 NZ NZ333441A patent/NZ333441A/xx not_active IP Right Cessation
- 1997-06-24 AU AU34090/97A patent/AU721942B2/en not_active Expired
- 1997-06-24 EP EP97930203A patent/EP0912184B1/en not_active Expired - Lifetime
- 1997-06-24 UA UA99010342A patent/UA65542C2/uk unknown
- 1997-06-24 RU RU99101117/14A patent/RU2183959C2/ru active
- 1997-06-24 DE DE69715862T patent/DE69715862T2/de not_active Expired - Lifetime
-
1998
- 1998-12-23 NO NO19986111A patent/NO317335B1/no not_active IP Right Cessation
-
2008
- 2008-03-04 JP JP2008053174A patent/JP4767982B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0912184B1 (en) | 2002-09-25 |
| NO986111L (no) | 1999-02-23 |
| WO1997049406A1 (en) | 1997-12-31 |
| CN1228024A (zh) | 1999-09-08 |
| CN1108799C (zh) | 2003-05-21 |
| HK1018745A1 (en) | 2000-01-07 |
| ATE224718T1 (de) | 2002-10-15 |
| RU2183959C2 (ru) | 2002-06-27 |
| BR9710693A (pt) | 2000-01-11 |
| ES2184106T3 (es) | 2003-04-01 |
| DE69715862T2 (de) | 2003-04-10 |
| JP4767982B2 (ja) | 2011-09-07 |
| EP0912184A1 (en) | 1999-05-06 |
| DK0912184T3 (da) | 2002-11-25 |
| UA65542C2 (uk) | 2004-04-15 |
| PT912184E (pt) | 2002-12-31 |
| JP2008189676A (ja) | 2008-08-21 |
| US6184217B1 (en) | 2001-02-06 |
| DE69715862D1 (de) | 2002-10-31 |
| NO986111D0 (no) | 1998-12-23 |
| AU3409097A (en) | 1998-01-14 |
| JP2000514420A (ja) | 2000-10-31 |
| AU721942B2 (en) | 2000-07-20 |
| NZ333441A (en) | 1999-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO317335B1 (no) | Anvendelse av K-252A derivat for behandling av perifere og sentrale nerveforstyrrelser og cytokinoverproduksjon | |
| Wu et al. | Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition | |
| RU2715703C1 (ru) | Композиции, содержащие дубильные кислоты и их применение | |
| Galeotti et al. | St. John's Wort reduces neuropathic pain through a hypericin-mediated inhibition of the protein kinase C γ and ɛ activity | |
| Hao et al. | Bioengineered microglia-targeted exosomes facilitate Aβ clearance via enhancing activity of microglial lysosome for promoting cognitive recovery in Alzheimer's disease | |
| JP2011520814A (ja) | 神経変性疾患を予防および治療するための方法 | |
| US20160158166A1 (en) | Methods of reducing brain cell apoptosis | |
| Miyazaki et al. | Therapeutic strategy of targeting astrocytes for neuroprotection in Parkinson's disease | |
| AU2021390590B2 (en) | Antiinflammatory compositions comprising cannabidiol, delta-9- tetrahydrocannabinol and linalool | |
| Phạm et al. | MAO-B inhibitor, KDS2010, alleviates spinal nerve ligation-induced neuropathic pain in rats through competitively blocking the BDNF/TrkB/NR2B signaling | |
| WO2021163613A1 (en) | Method of decreasing amyloid beta monomer levels in patients with cognitive decline | |
| Pang et al. | Activation of spinal ERK signaling pathway contributes to pain-related responses induced by scorpion Buthus martensi Karch venom | |
| US20240424045A1 (en) | Berberis composition for cognitive health | |
| Tripathi et al. | Alterations in the sensitivity of 5th receptor subtypes following chronic Asvagandha treatment in rats | |
| EP3285761A1 (en) | Parthenolide and its derivatives for use in the treatment of axonal damage | |
| KR100479362B1 (ko) | 중추또는말초신경계장애및싸이토카인과잉생산치료를위한k-252a유도체 | |
| MXPA99000278A (en) | Use of derivative of k-252a for the treatment of central peripheral nerve disorders and citoqu overproduction | |
| RU2841658C1 (ru) | Способ снижения уровней мономеров бета-амилоида у пациентов со снижением когнитивных способностей | |
| KR102573243B1 (ko) | 신경병증성 통증 치료 또는 예방용 enu 약학 조성물 | |
| CA2258662C (en) | Use of k-252a derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction | |
| WO2016166565A1 (en) | Use of a withania extract for the treatment of alpha synucleinopathies | |
| Ezekiel et al. | Comparative Effects of Taurine and Vitamin E in Acetaminophen-Induced Oxidative Stress on Learning and Memory in Male Wistar Rats | |
| AU3534500A (en) | Use of k-252a derivative for the treatment of peripheral or central nerve disorders, ... | |
| CN120152704A (zh) | 留兰香提取物在视网膜神经营养中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |